What Regeneron's 8-K filings say: 4 filings, latest Jul 6, 2026

Regeneron filed its latest 8-K with the SEC on Jul 6, 2026. It discusses acquisition announced, data investment and margin pressure.

Public (REGN)Biotechnology Research10,000+ employeesregeneron.comLinkedIn

Filed: Jul 6, 2026
Filings: 4
Signals: 10

8-K · latest 9

What Regeneron's 8-K filings say

8-K
Filed Jul 6, 2026 · 3 signals
SEC EDGAR
- Acquisition announcedNeutral
  Regeneron announces $127M charge for acquiring in-process R&D via licensing/collaboration deals.
  Regeneron is investing $127M in external innovation through collaboration and licensing deals, creating a need to integrate and develop these new R&D assets.
  $127M
  Acquired in-process research and development (IPR&D) charge related to collaboration and licensing agreements
- Margin pressureNegative
  Regeneron to take a $127M charge in Q2 2026, negatively impacting earnings per share by ~$1.00.
  The company is recording a significant $127 million pre-tax charge for acquired in-process R&D from collaboration and licensing deals.
  $127M
  Acquired in-process research and development (IPR&D) pre-tax charge
8-K
Filed Jun 17, 2026 · 1 signal
SEC EDGAR
- Governance changeNegative
  Regeneron faces shareholder dissent with over 20% 'Against' votes for three re-elected directors.
  Significant shareholder opposition to the re-election of directors Joseph L.
  30%
  Approximate shareholder votes 'Against' the re-election of director Joseph L. Goldstein, M.D. (30.9M against vs 72.4M for).
  PricewaterhouseCoopers LLP
8-K
Filed Apr 8, 2026 · 3 signals
SEC EDGAR
- Material contractNeutral
  Regeneron discloses $102M charge for R&D collaboration and licensing agreements in Q1 2026.
  The $102 million charge for acquired in-process research and development (IPR&D) indicates significant recent investment in external innovation through new partnerships.
  $102M
  Acquired in-process research and development (IPR&D) charge related to collaboration and licensing agreements.
- Data investmentNeutral
  Regeneron flags $102M charge for acquired R&D, signaling potential data integration needs.
  Regeneron is investing heavily in external innovation via collaboration and licensing agreements, leading to a significant $102M charge.
  $102M
  Acquired in-process research and development (IPR&D) charge for collaboration and licensing agreements.
- Margin pressureNegative
  Regeneron flags $102M Q1 charge, reducing EPS by ~$0.81 due to R&D deals.
  Regeneron anticipates a $102M pre-tax charge for acquired R&D in Q1 2026, which will directly reduce profitability.
  $102M
  Acquired in-process research and development (IPR&D) charge
8-K
Filed Jan 12, 2026 · 3 signals
SEC EDGAR
- Acquisition announcedNeutral
  Regeneron to record $19M charge for acquired in-process R&D in Q4 2025
  Regeneron is investing in external innovation by acquiring research and development assets, resulting in a $19 million charge.
  $19M
  Acquired in-process research and development (IPR&D) charge
  J.P. Morgan
- Sustainability investmentPositive
  Regeneron takes $60M charge for charitable donation program with a total commitment of up to $200M.
  Regeneron recorded a $60 million charge in Q4 2025 as part of a commitment to match up to $200 million in donations to a patient support fund.
  $60M
  Charge for matching contribution in Q4 2025, out of a total program commitment of up to $200 million.
  Good Days
- RestructuringNeutral
  Regeneron signals asset acquisition with $19M R&D charge impacting Q4 2025 earnings.
  Regeneron is absorbing new R&D assets, indicated by a $19M charge for in-process research and development (IPR&D) that negatively impacts EPS by $0.14.
  $19M
  Acquired in-process research and development (IPR&D) charge for Q4 2025

Showing 9 of 10 filing signals. The Signal API returns all of them.

Get them with one API call

Signal API · MCP

Track Regeneron with the Signal API

One POST /v1/companies/enrich call with regeneron.com returns Regeneron 8-K signals (sec-8k), each with its source. Or ask Claude through MCP.

Start Free1,000 free creditsUse it in Claude via MCP

2 credits per signal returned; zero-result calls are free. Endpoint reference

curl -X POST https://signals.autobound.ai/v1/companies/enrich \
  -H "X-API-KEY: $AUTOBOUND_API_KEY" \
  -H "Content-Type: application/json" \
  -d '{"domain":"regeneron.com","signal_types":["sec-8k"],"limit":20}'

Same industry

Questions about Regeneron 8-K

When did Regeneron file its latest 8-K?

Regeneron filed its latest 8-K on Jul 6, 2026. The one before it was filed on Jun 17, 2026.

What did Regeneron disclose in its latest 8-K?

From the filing dated Jul 6, 2026: Regeneron announces $127M charge for acquiring in-process R&D via licensing/collaboration deals.

Where can I read Regeneron's 8-K filing?

The full filing is on SEC EDGAR: https://www.sec.gov/Archives/edgar/data/872589/000110465926080562/tm2619682d1_8k.htm. This page summarizes what the filing says and links to it.

Source. Current reports (Form 8-K) filed with the SEC. Every card links to the filing on EDGAR.

Method. Insights are extracted from the filing text and grouped by category. Numbers are quoted from the filing.

Data as of Sep 30, 2026.

How this data is built →Get it from the Signal API →

What Regeneron's 8-K filings say: 4 filings, latest Jul 6, 2026

What Regeneron's 8-K filings say

Track Regeneron with the Signal API

8-K at related companies

Questions about Regeneron 8-K